HKEX

APOLLO FUTURE MOBILITY GROUP announces key executive appointments and ramping up of AFMG German innovation hub to reinforce its ESO presence

Thursday, September 23, 2021 - 8:11am

Also, a new AFMG Facility, opened in Wolfsburg, Germany in May, is ramping up rapidly to reinforce the Group's presence in the engineering service outsourcing ("ESO") space.

Key Points: 
  • Also, a new AFMG Facility, opened in Wolfsburg, Germany in May, is ramping up rapidly to reinforce the Group's presence in the engineering service outsourcing ("ESO") space.
  • Mr. Thorsten Falldorf has been appointed Head of Research & Development Wolfsburg, heading the AFMG German Innovation Hub, effective since 1 May 2021.
  • The AFMG German Operations facilitate the development of projects for the mobility of tomorrow and promote future innovations.
  • Apollo Future Mobility Group Limited (HKEx stock code: 860) is a leading integrated mobility technology solution provider with proprietary and disruptive mobility technologies.

Cecelia Zhong Joins Interactive Brokers as Executive Director

Thursday, September 23, 2021 - 2:00am

Interactive Brokers Group (Nasdaq: IBKR), a global brokerage firm, today announced that Cecelia Zhong joined on September 6, as Executive Director focusing on business development for Greater China in a newly created position.

Key Points: 
  • Interactive Brokers Group (Nasdaq: IBKR), a global brokerage firm, today announced that Cecelia Zhong joined on September 6, as Executive Director focusing on business development for Greater China in a newly created position.
  • Reporting to David Friedland, Managing Director-Asia Pacific Operations at Interactive Brokers, Cecelia is based in IBKRs Hong Kong office and will be dedicated to the companys growth and expansion in China.
  • We are excited to welcome Cecelia to Interactive Brokers and her appointment reinforces our commitment to China and serving our clients in Asia, said Mr. Friedland.
  • Ms. Zhong added, I am pleased to join Interactive Brokers and work alongside such an accomplished team.

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Wednesday, September 22, 2021 - 11:00pm

"We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond," said Carl Hansen, Ph.D., CEO and President of AbCellera.

Key Points: 
  • "We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond," said Carl Hansen, Ph.D., CEO and President of AbCellera.
  • By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access.
  • Under the terms of the agreement, Everest will have the rights to develop and commercialize antibodies resulting from the collaboration.
  • AbCellera will receive research payments and is eligible to receive from Everest downstream clinical and commercial milestone payments and royalties on net sales of products.

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Wednesday, September 22, 2021 - 11:00pm

AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, Everest) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.

Key Points: 
  • AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, Everest) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.
  • We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond, said Carl Hansen, Ph.D., CEO and President of AbCellera.
  • By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access.
  • Under the terms of the agreement, Everest will have the rights to develop and commercialize antibodies resulting from the collaboration.

Baidu and China Gas Collaborate to Accelerate Smart Energy Transformation

Tuesday, September 21, 2021 - 1:57pm

Under the first stage of their partnership, worth RMB 936 million yuan, Baidu will expedite China Gas' move to the cloud and harness its AI capabilities to build customized applications including smart monitoring, smart scheduling, gas usage prediction, and smart customer services.

Key Points: 
  • Under the first stage of their partnership, worth RMB 936 million yuan, Baidu will expedite China Gas' move to the cloud and harness its AI capabilities to build customized applications including smart monitoring, smart scheduling, gas usage prediction, and smart customer services.
  • "With over 40 million users, China Gas has its sights set beyond gas to new AI technologies and services for public benefit," said Yong Huang, executive president of China Gas.
  • Incorporate initiatives from Baidu into China Gas to train professionals and management specialized in digital transformation, including "AICA AI Chief Architect Development Program".
  • China Gas Holdings Limited ("China Gas", stock code: 384.HK) is one of the largest trans-regional comprehensive energy suppliers in China engaged in investment and construction, operation and management, warehousing and logistics, trading and distribution businesses of various gas and new energy projects.

Ping An Upgrades Zhen Xiang RUN Health Services Plan

Monday, September 20, 2021 - 4:17pm

HONG KONG andSHANGHAI, Sept. 20, 2021 /PRNewswire/ -- Ping An Life has upgraded its Zhen Xiang RUN Health Services Plan with several new critical illness insurance products, announced Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318).

Key Points: 
  • HONG KONG andSHANGHAI, Sept. 20, 2021 /PRNewswire/ -- Ping An Life has upgraded its Zhen Xiang RUN Health Services Plan with several new critical illness insurance products, announced Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318).
  • Ping An Zhen Xiang RUN, launched earlier this year, provides customers with dedicated family doctors and professional health records for a worry-free, efficient and affordable health service experience.
  • The enhancements of Ping An Zhen Xiang RUN show Ping An Life's focus on customers' health needs and the effective allocation of high quality medical and health resources.
  • Ping An focuses on two over-arching domains of activity, "pan financial assets" and "pan health care", covering the provision of financial and health care services through our integrated financial services platform and our ecosystems; in financial services, health care, auto services and smart city services.

Ping An Upgrades Zhen Xiang RUN Health Services Plan

Monday, September 20, 2021 - 4:08pm

HONG KONG andSHANGHAI, Sept. 20, 2021 /PRNewswire/ -- Ping An Life has upgraded its Zhen Xiang RUN Health Services Plan with several new critical illness insurance products, announced Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318).

Key Points: 
  • HONG KONG andSHANGHAI, Sept. 20, 2021 /PRNewswire/ -- Ping An Life has upgraded its Zhen Xiang RUN Health Services Plan with several new critical illness insurance products, announced Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318).
  • Ping An Zhen Xiang RUN, launched earlier this year, provides customers with dedicated family doctors and professional health records for a worry-free, efficient and affordable health service experience.
  • The enhancements of Ping An Zhen Xiang RUN show Ping An Life's focus on customers' health needs and the effective allocation of high quality medical and health resources.
  • Ping An focuses on two over-arching domains of activity, "pan financial assets" and "pan health care", covering the provision of financial and health care services through our integrated financial services platform and our ecosystems; in financial services, health care, auto services and smart city services.

Ninja Brings the Coffeeshop Experience to Your Kitchen

Monday, September 20, 2021 - 2:00pm

NEEDHAM, Mass., Sept. 20, 2021 /PRNewswire/ -- The summer heat may be fading, but consumers' at-home coffee habits are here to stay. Ninja (HKEX: 1691.HK), the number one brand in small kitchen appliances*, is helping consumers master the art of home brewing with the launch of the versatile Ninja® DualBrew Pro Specialty Coffee System, now offering the choice of brewing their favorite grounds or pods. With this launch, Ninja aims to empower consumers with the tools they need to create coffeeshop-style and autumn-inspired beverages as they transition seasons at home.

Key Points: 
  • With this launch, Ninja aims to empower consumers with the tools they need to create coffeeshop-style and autumn-inspired beverages as they transition seasons at home.
  • Now through October 4, consumers who purchase the Ninja DualBrew Pro Specialty Coffee System on NinjaKitchen.com will receive a code redeemable for a free bag of Ninja and Irving Farm New York's co-branded Ninja Pro Blend.
  • Additionally, Ninja will offer a one-day 20 percent discount in celebration of National Coffee Day on October 1.
  • "Irving Farm New York is thrilled to team up with Ninja to offer an exclusive blend that brings the coffeeshop experience to your home," said Zach Popoff, Head of Marketing for Irving Farm New York.

Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19

Sunday, September 19, 2021 - 12:29pm

The pseudovirus and authentic virus studies demonstrated that the Therapy retains neutralization activity against the Alpha and Delta variants.

Key Points: 
  • The pseudovirus and authentic virus studies demonstrated that the Therapy retains neutralization activity against the Alpha and Delta variants.
  • Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology of the Chinese Academy of Sciences.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

Friday, September 17, 2021 - 12:40am

This Phase I clinical trial is to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and recommended Phase II dose of SN1011 in the treatment of autoimmune disease.

Key Points: 
  • This Phase I clinical trial is to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and recommended Phase II dose of SN1011 in the treatment of autoimmune disease.
  • Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases.
  • Sinovent is a global biopharmaceutical company focused on discovery, development, and commercialization of innovative medicines to address significant unmet clinical needs.
  • Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development.